Table 2 Evolution of ED95 after each cohort
Prilocaine Dose, mg | ||||||||
|---|---|---|---|---|---|---|---|---|
30 | 35 | 40 | 45 | 50 | 55 | |||
Working model | ||||||||
0.5 | 0.75 | 0.90 | 0.95 | 0.98 | 0.99 | |||
Cohort | Administered dose, mg | Clinical response | Updated Estimated Probability of Response | |||||
1 | 45 | S,S,S,S | 0.66 | 0.89 | 0.97 | 0.99 | 1.00 | 1.00 |
2 | 40 | S,S,S,S | 0.73 | 0.93 | 0.99 | 0.99 | 1.00 | 1.00 |
3 | 40 | S,S,S,S | 0.76 | 0.94 | 0.99 | 1.00 | 1.00 | 1.00 |
4 | 35 | F,F,S,F | 0.48 | 0.73 | 0.88 | 0.93 | 0.97 | 0.99 |
5 | 50 | S,S,S,S | 0.49 | 0.74 | 0.89 | 0.95 | 0.98 | 0.99 |
6 | 45 | S,S,S,S | 0.51 | 0.76 | 0.91 | 0.95 | 0.98 | 0.99 |
7 | 45 | S,S,S,S | 0.53 | 0.78 | 0.92 | 0.96 | 0.99 | 1.00 |
8 | 45 | S,S,S,S | 0.54 | 0.79 | 0.93 | 0.97 | 0.99 | 0.99 |
9 | 40 | S,S,S,F | 0.50 | 0.75 | 0.90 | 0.95 | 0.98 | 0.99 |
10 | 45 | S,S,S,F | 0.46 | 0.71 | 0.87 | 0.9322 | 0.9702 | 0.99 |